+

WO2002016602A3 - Compositions and methods for the diagnosis and treatment of tumor - Google Patents

Compositions and methods for the diagnosis and treatment of tumor Download PDF

Info

Publication number
WO2002016602A3
WO2002016602A3 PCT/US2001/026626 US0126626W WO0216602A3 WO 2002016602 A3 WO2002016602 A3 WO 2002016602A3 US 0126626 W US0126626 W US 0126626W WO 0216602 A3 WO0216602 A3 WO 0216602A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
tumor
diagnosis
treatment
methods
Prior art date
Application number
PCT/US2001/026626
Other languages
French (fr)
Other versions
WO2002016602A2 (en
Inventor
Avi J Ashkenazi
Audrey Goddard
Paul J Godowski
Austin L Gurney
Paul Polakis
P Mickey Williams
William I Wood
Thomas D Wu
Zemin Zhang
Original Assignee
Genentech Inc
Avi J Ashkenazi
Audrey Goddard
Paul J Godowski
Austin L Gurney
Paul Polakis
P Mickey Williams
William I Wood
Thomas D Wu
Zemin Zhang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2000/023328 external-priority patent/WO2001016318A2/en
Priority claimed from PCT/US2000/032678 external-priority patent/WO2001040466A2/en
Priority claimed from PCT/US2001/006520 external-priority patent/WO2001068848A2/en
Priority claimed from PCT/US2001/017800 external-priority patent/WO2001093983A1/en
Priority claimed from PCT/US2001/019692 external-priority patent/WO2002000690A2/en
Priority claimed from PCT/US2001/021066 external-priority patent/WO2002008288A2/en
Priority claimed from PCT/US2001/021735 external-priority patent/WO2002008284A2/en
Priority to CA002420193A priority Critical patent/CA2420193A1/en
Priority to AU2001286785A priority patent/AU2001286785B2/en
Priority to MXPA03001643A priority patent/MXPA03001643A/en
Priority to JP2002522275A priority patent/JP2004520810A/en
Application filed by Genentech Inc, Avi J Ashkenazi, Audrey Goddard, Paul J Godowski, Austin L Gurney, Paul Polakis, P Mickey Williams, William I Wood, Thomas D Wu, Zemin Zhang filed Critical Genentech Inc
Priority to AU8678501A priority patent/AU8678501A/en
Priority to EP01966255A priority patent/EP1311668A2/en
Priority to KR1020037002672A priority patent/KR100607611B1/en
Publication of WO2002016602A2 publication Critical patent/WO2002016602A2/en
Publication of WO2002016602A3 publication Critical patent/WO2002016602A3/en
Priority to AU2006230703A priority patent/AU2006230703A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
PCT/US2001/026626 2000-08-24 2001-08-23 Compositions and methods for the diagnosis and treatment of tumor WO2002016602A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
KR1020037002672A KR100607611B1 (en) 2000-08-24 2001-08-23 Methods for Diagnosing and Treating Tumors and Compositions for the Same
EP01966255A EP1311668A2 (en) 2000-08-24 2001-08-23 Compositions and methods for the diagnosis and treatment of tumor
AU8678501A AU8678501A (en) 2000-08-24 2001-08-23 Compositions and methods for the diagnosis and treatment of tumor
CA002420193A CA2420193A1 (en) 2000-08-24 2001-08-23 Compositions and methods for the diagnosis and treatment of tumor
JP2002522275A JP2004520810A (en) 2000-08-24 2001-08-23 Compositions and methods for tumor diagnosis and treatment
MXPA03001643A MXPA03001643A (en) 2000-08-24 2001-08-23 Compositions and methods for the diagnosis and treatment of tumor.
AU2001286785A AU2001286785B2 (en) 2000-08-24 2001-08-23 Compositions and methods for the diagnosis and treatment of tumor
AU2006230703A AU2006230703A1 (en) 2000-08-24 2006-10-18 Compositions and methods for the diagnosis and treatment of tumor

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
PCT/US2000/023328 WO2001016318A2 (en) 1999-09-01 2000-08-24 Secreted and transmembrane polypeptides and nucleic acids encoding the same
USPCT/US00/23328 2000-08-24
USPCT/US00/32678 2000-12-01
PCT/US2000/032678 WO2001040466A2 (en) 1999-12-01 2000-12-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same
PCT/US2001/006520 WO2001068848A2 (en) 2000-03-01 2001-02-28 Secreted and transmembrane polypeptides and nucleic acids encoding the same
USPCT/US01/06520 2001-02-28
PCT/US2001/017800 WO2001093983A1 (en) 2000-06-02 2001-06-01 Secreted and transmembrane polypeptides and nucleic acids encoding the same
USPCT/US01/17800 2001-06-01
USPCT/US01/19692 2001-06-20
PCT/US2001/019692 WO2002000690A2 (en) 2000-06-23 2001-06-20 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
USPCT/US01/21066 2001-06-29
PCT/US2001/021066 WO2002008288A2 (en) 2000-07-20 2001-06-29 Secreted and transmembrane polypeptides and nucleic acids encoding the same
USPCT/US01/21735 2001-07-09
PCT/US2001/021735 WO2002008284A2 (en) 2000-07-20 2001-07-09 Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis

Publications (2)

Publication Number Publication Date
WO2002016602A2 WO2002016602A2 (en) 2002-02-28
WO2002016602A3 true WO2002016602A3 (en) 2003-02-06

Family

ID=27567433

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/026626 WO2002016602A2 (en) 2000-08-24 2001-08-23 Compositions and methods for the diagnosis and treatment of tumor

Country Status (5)

Country Link
JP (1) JP2004520810A (en)
AU (2) AU2001286785B2 (en)
CA (1) CA2420193A1 (en)
MX (1) MXPA03001643A (en)
WO (1) WO2002016602A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050123925A1 (en) * 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20030228319A1 (en) * 2002-04-16 2003-12-11 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2305710A3 (en) * 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
US20120045390A1 (en) * 2002-09-11 2012-02-23 Genentech, Inc. Composition and Methods for the Diagnosis and Treatment of Tumor
WO2004060270A2 (en) * 2002-10-18 2004-07-22 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1583503A4 (en) * 2002-12-20 2006-08-09 Biogen Idec Inc Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
WO2005002582A2 (en) 2003-07-02 2005-01-13 Genentech, Inc. Trp-p8 active compounds and therapeutic treatment methods
KR20070036089A (en) 2004-07-02 2007-04-02 제넨테크, 인크. Methods and therapeutic compositions for non-Hodgkin's lymphoma
JP4547533B2 (en) * 2004-12-15 2010-09-22 独立行政法人産業技術総合研究所 Nucleolytic enzyme
JPWO2006082851A1 (en) * 2005-02-02 2008-06-26 国立大学法人 東京大学 Epiglycanin related mucin
CN101449162B (en) * 2006-05-18 2013-07-31 分子压型学会股份有限公司 System and method for determining individualized medical intervention for a disease state
EA018456B1 (en) * 2007-07-27 2013-08-30 Имматикс Байотекнолоджиз Гмбх NEW IMMUNOGENIC EPITOPES FOR IMMUNOTHERAPY
WO2009080830A1 (en) 2007-12-26 2009-07-02 Biotest Ag Immunoconjugates targeting cd138 and uses thereof
CN101945892B (en) 2007-12-26 2017-11-24 生物测试股份公司 For the method and reagent of the targeting for improving the tumour cell to expressing CD138
PL2801584T3 (en) 2007-12-26 2019-12-31 Biotest Ag Agents targeting CD138 and uses thereof
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0388914A1 (en) * 1989-03-24 1990-09-26 BEHRINGWERKE Aktiengesellschaft Monoclonal antibodies against tumor associated antigen, their preparation and use
WO1999040189A2 (en) * 1998-02-09 1999-08-12 Genset Cdnas encoding secreted proteins
WO1999046281A2 (en) * 1998-03-10 1999-09-16 Genentech, Inc. Novel polypeptides and nucleic acids encoding the same
WO2000012708A2 (en) * 1998-09-01 2000-03-09 Genentech, Inc. Further pro polypeptides and sequences thereof
WO2000023108A1 (en) * 1998-10-19 2000-04-27 Diadexus Llc Method of diagnosing, monitoring, staging, imaging and treating prostate cancer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0388914A1 (en) * 1989-03-24 1990-09-26 BEHRINGWERKE Aktiengesellschaft Monoclonal antibodies against tumor associated antigen, their preparation and use
WO1999040189A2 (en) * 1998-02-09 1999-08-12 Genset Cdnas encoding secreted proteins
WO1999046281A2 (en) * 1998-03-10 1999-09-16 Genentech, Inc. Novel polypeptides and nucleic acids encoding the same
WO2000012708A2 (en) * 1998-09-01 2000-03-09 Genentech, Inc. Further pro polypeptides and sequences thereof
WO2000023108A1 (en) * 1998-10-19 2000-04-27 Diadexus Llc Method of diagnosing, monitoring, staging, imaging and treating prostate cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
R. CHARI ET AL.: "Immunoconjugates containing novel maytansinoids: promising anticancer drugs.", CANCER RESEARCH, vol. 52, no. 1, 1 January 1992 (1992-01-01), Baltimore, MD, USA, pages 127 - 131, XP000453560 *
See also references of EP1311668A2 *

Also Published As

Publication number Publication date
MXPA03001643A (en) 2004-05-14
JP2004520810A (en) 2004-07-15
CA2420193A1 (en) 2002-02-28
AU2001286785B2 (en) 2006-08-17
AU8678501A (en) 2002-03-04
WO2002016602A2 (en) 2002-02-28

Similar Documents

Publication Publication Date Title
WO2002016429A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2003024392A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2003000113A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2003088808A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2006110760A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2002016581A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2006029183A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004112829A3 (en) Compositions and methods for the diagnosis and treatment of tumors of glial origin
MXPA05005107A (en) Compositions and methods for the diagnosis and treatment of tumor.
EP2067472A8 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2007001851A3 (en) Compositions and methods for the diagnosis and treatment of tumor
AU6147401A (en) Compositions and methods for the treatment of cancer
WO2005049075A3 (en) Compositions and methods for the treatment of tumor of hematopoietic origin
WO2002016602A3 (en) Compositions and methods for the diagnosis and treatment of tumor
AU3227700A (en) Skin sanitizing compositions
WO2004024063A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2005063299A3 (en) Compositions and methods for the treatment of tumor of hematopoietic origin
WO2004096124A3 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2001255730A1 (en) Methods and compositions for the treatment of cardiac indications
WO2001040465A3 (en) Compositions and methods for the treatment of immune related diseases
AU2001283199A1 (en) Methods and compositions for the diagnosis and treatment of brown adipose cell disorders
MXPA03001644A (en) Compositions and methods for the diagnosis and treatment of tumor.
MXPA05008293A (en) Compositions and methods for the diagnosis and treatment of tumor.
WO2004019857A3 (en) Achaete-scute like-2 polypeptides and encoding nucleic acids and methods for the diagnosis and treatment of tumor
WO2003053334A3 (en) Compositions and methods for the diagnosis and treatment of tumor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001286785

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003/01205

Country of ref document: ZA

Ref document number: 200301205

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2420193

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/001643

Country of ref document: MX

Ref document number: 2002522275

Country of ref document: JP

Ref document number: 1020037002672

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2001966255

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020037002672

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2001966255

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 1020037002672

Country of ref document: KR

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载